PEOPLE - NHS Quality Improvement Scotland makes appointment:
This article was originally published in Clinica
Professor Sir Graham Teasdale has been appointed to chair the board of NHS Quality Improvement Scotland for a four-year term. Professor Teasdale has over 25 years of "frontline experience" in the NHS and is, among other things, president of the Royal College of Physicians and Surgeons of Glasgow. NHS-QIS is the counterpart of the National Institute for Health and Clinical Excellence (for the NHS in England and Wales); while it often provides technology usage policy based on NICE decisions, NHS-QIS has also led on key technology areas, such as B-type natriuretic peptide (BNP) testing for cardiac failure, issued in May 2005 (see Clinica No 1156, p 8).
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.